The Point Of No Risk

“When everyone believes something is risky, their unwillingness to buy usually reduces its price to the point where it’s not risky at all. Broadly negative opinion can make it the least risky thing, since all optimism has been driven out of its price.”

This Howard Marks quote is the perfect way to describe what’s happened with biotech stocks this year. Through the first 28 days of 2016, the SPDR S&P Biotech ETF fell 34%. After 153 days and a 52% gain, it’s apparent that prices declined to the point where they weren’t risky at all.

Below is a chart of the Biotechnology Index that has data going back to 1992. The 28 day start to 2016 was the worst performance over such a time since the bursting of the tech bubble.

biotech

Of course this realization is only obvious with the benefit of hindsight. We certainly couldn’t know in February when the selling would abate. Furthermore, the idea that assets get more attractive as they decline, while generally true, is extraordinarily difficult to implement in the real world. Nobody taps you on the shoulder and says “son, we’ve arrived at that point.”  Here’s an extreme example; from September 1929 through the end of 1931, stocks fell 78%. It would have appeared at that point that prices reflected all of the pessimism. They didn’t. Stocks fell another 50% in the first seven months of 1932.

We know that expected returns rise as actual returns fall, but very few people can turn that knowledge into successful investing results.

Source: Memo To Oaktree Clients

This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.

The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.

References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.

The Compound Media, Inc., an affiliate of Ritholtz Wealth Management, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. Investments in securities involve the risk of loss. For additional advertisement disclaimers see here: https://www.ritholtzwealth.com/advertising-disclaimers

Please see disclosures here.